Metronidazole

Manufacturer
Mayne Pharma Inc. | G Production Inc.
Effective date
2024-10-31
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-05-31 21:33:14

Label at a glance#

ProductMetronidazole
Active ingredientMETRONIDAZOLE
Label structure17 sections

Indications and uses

Metronidazole Gel, 1% is indicated for the topical treatment of inflammatory lesions of rosacea.

Dosage and administration

Cleanse treated areas before the application of Metronidazole Gel. Apply and rub in a thin film of Metronidazole Gel once daily to affected area(s). Cosmetics may be applied after the application of Metronidazole Gel. For topical use only, not for oral, ophthalmic, or intravaginal use.

Storage and handling

How Supplied Metronidazole Gel is clear, colorless to pale yellow in color, and supplied as follows: 55 gram pump – NDC 68308-663-55 60 gram tube – NDC 68308-663-60 Storage and Handling Store at controlled room temperature: 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (59° and 86°F).

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Metronidazole Gel, 1% is indicated for the topical treatment of inflammatory lesions of rosacea. 

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

  • Cleanse treated areas before the application of Metronidazole Gel.
  • Apply and rub in a thin film of Metronidazole Gel once daily to affected area(s). 
  • Cosmetics may be applied after the application of Metronidazole Gel. 
  • For topical use only, not for oral, ophthalmic, or intravaginal use.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Gel, 1%. Metronidazole Gel is a clear, colorless to pale yellow gel. Each gram of Metronidazole Gel contains 10 mg (1%) of metronidazole.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Metronidazole Gel is contraindicated in patients with a history of hypersensitivity to metronidazole or to any other ingredient in the formulation.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION


5.1 Neurologic Disease

SPL UNCLASSIFIED SECTION

Peripheral neuropathy, characterized by numbness or paresthesia of an extremity, has been reported in patients treated with systemic metronidazole. Peripheral neuropathy has been reported with the post approval use of topical metronidazole. Immediately reevaluate Metronidazole Gel therapy if abnormal neurologic signs appear. Administer metronidazole with caution to patients with central nervous system diseases.

5.2 Blood Dyscrasias

SPL UNCLASSIFIED SECTION

Metronidazole is a nitroimidazole; use with care in patients with evidence of, or history of, blood dyscrasia.

5.3 Contact Dermatitis

SPL UNCLASSIFIED SECTION

Irritant and allergic contact dermatitis have been reported with Metronidazole Gel. If dermatitis occurs, patients may need to discontinue use.

5.4 Eye Irritation

SPL UNCLASSIFIED SECTION

Topical metronidazole has been reported to cause tearing of the eyes.  Avoid contact with the eyes.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following clinically significant adverse reactions are described elsewhere in the labeling:

  • Neurologic Disease [see Warnings and Precautions (5.1)]
    Contact Dermatitis [see Warnings and Precautions (5.3)] 
  • Eye Irritation [see Warnings and Precautions (5.4)]

6.1 Clinical Trials Experience

SPL UNCLASSIFIED SECTION

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In a controlled clinical trial, 557 subjects used Metronidazole Gel and 189 subjects used the gel vehicle once daily for up to 10 weeks. The following table summarizes selected adverse reactions that occurred at a rate of ≥1% and at a higher rate than vehicle:

Table 1: Adverse Reactions That Occurred at a Rate of ≥1% and Higher Than Vehicle in Subjects Treated with Metronidazole Gel for Up to 10 Weeks
Preferred TermMetronidazole GelGel Vehicle
   Influenza8 (1.4)1 (0.5)
   Upper respiratory tract infection14 (2.5)4 (2.1)
   Urinary tract infection6 (1.1)1 (0.5)
   Headache12 (2.2)1 (0.5)
   Contact dermatitis7 (1.3)1 (0.5)
   Hypertension6 (1.1)1 (0.5)
Table 2: Local Cutaneous Signs and Symptoms of Irritation That Were Worse Than Baseline in Subjects Treated with Metronidazole Gel for Up to 10 Weeks
Metronidazole GelGel Vehicle
Sign/SymptomN= 544 N (%)N= 184 N (%)
Dryness138 (25.4)63 (34.2)
   Mild93 (17.1)41 (22.3)
   Moderate42 (7.7)20 (10.9)
   Severe3 (0.6)2 (1.1)
Scaling134 (24.6)60 (32.6)
   Mild88 (16.2)32 (17.4)
   Moderate43 (7.9)27 (14.7)
   Severe3 (0.6)1 (0.5)
Pruritus86 (15.8)35 (19.0)
   Mild53 (9.7)21 (11.4)
   Moderate27 (5.0)13 (7.1)
   Severe6 (1.1)1 (0.5)
Stinging/burning56 (10.3)28 (15.2)
   Mild39 (7.2)18 (9.8)
   Moderate7 (1.3)9 (4.9)
   Severe10 (1.8)1 (0.5)

The following additional adverse experiences have been reported with the topical use of metronidazole: transient redness, metallic taste, tingling or numbness of extremities, and nausea.

6.2 Post Marketing Experience

SPL UNCLASSIFIED SECTION

The following adverse reaction has been identified during post- approval use of topical metronidazole. Because this reaction is reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.

Nervous System Disorders: Peripheral neuropathy 
Ophthalmic Adverse Reactions: Tearing of the eyes

7 DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. Use caution when prescribing for patients who are receiving anticoagulant treatment.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION


8.1 Pregnancy

PREGNANCY SECTION

Risk Summary
Available data have not established an association with metronidazole use during pregnancy and major birth defects, miscarriage or other adverse maternal or fetal outcomes. No fetotoxicity was observed after oral administration of metronidazole in pregnant rats or mice. The available data do not allow the calculation of relevant comparisons between the systemic exposures of metronidazole observed in animal studies to the systemic exposures that would be expected in humans after topical use of Metronidazole Gel.

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

8.2 Lactation

LABOR & DELIVERY SECTION

Risk Summary
It is not known whether metronidazole is present in human milk after topical administration. Published literature reports the presence of metronidazole in human milk after oral administration. There are no data on the effects of metronidazole on milk production. Because of the potential for serious adverse reactions, advise patients that breastfeeding is not recommended during treatment with Metronidazole Gel.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness of Metronidazole Gel have not been established in pediatric patients.

8.5 Geriatric Use

GERIATRIC USE SECTION

Sixty-six subjects aged 65 years and older were treated with Metronidazole Gel in the clinical study. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out..

11 DESCRIPTION

DESCRIPTION SECTION

Metronidazole topical gel, 1% is a nitroimidazole for topical use. Metronidazole Gel is a clear, colorless to pale yellow, aqueous gel. Each gram contains 10 mg of metronidazole. Chemically, metronidazole is 2-methyl-5-nitro-1 H-imidazole-1-ethanol. The molecular formula for metronidazole is C6H9N3O3. It has the following structural formula:

Structural FormulaStructural Formula

Metronidazole has a molecular weight of 171.16. It is a white to pale yellow crystalline powder. It is slightly soluble in alcohol and has solubility in water of 10 mg/mL at 20˚C. Metronidazole belongs to the nitroimidazole class of compounds.
The inactive ingredients are betadex, edetate disodium, hydroxyethyl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparaben and purified water.

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION


12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

The mechanism of action of metronidazole in the treatment of rosacea is unknown.

12.2 Pharmacodynamics

PHARMACODYNAMICS SECTION

The pharmacodynamics of metronidazole in association with the treatment of rosacea are unknown.
Cardiac Electrophysiology: The effect of Metronidazole Gel on the QTc interval has not been adequately characterized.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

Topical administration of a one gram dose of Metronidazole Gel to the face of 13 patients with moderate to severe rosacea once daily for 7 days resulted in a mean ± SD Cmax of metronidazole of 32 ± 9 ng/mL.  The mean ± SD AUC(0-24) was 595 ± 154 ng*hr/mL. The mean Cmax and AUC(0-24) are less than 1% of the value reported for a single 250 mg oral dose of metronidazole. The time to maximum plasma concentration (Tmax) was 6-10 hours after topical application.

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION


13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats, but not in studies involving hamsters.
In several long-term studies in mice, oral doses of approximately 225 mg/m2/day or greater were associated with an increase in pulmonary tumors and lymphomas. Several long-term oral studies in the rat have shown statistically significant increases in mammary and hepatic tumors at doses >885 mg/m2/day.
Metronidazole has shown evidence of mutagenic activity in several in vitro bacterial assay systems. In addition, a dose-related increase in the frequency of micronuclei was observed in mice after intraperitoneal injections. An increase in chromosomal aberrations in peripheral blood lymphocytes was reported in patients with Crohn’s disease who were treated with 200 to 1200 mg/day of metronidazole for 1 to 24 months. However, in another study, no increase in chromosomal aberrations in circulating lymphocytes was observed in patients with Crohn’s disease treated with the drug for 8 months.

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

In a randomized, vehicle-controlled trial, 746 subjects with rosacea were treated with Metronidazole Gel or vehicle once daily for 10 weeks. Most subjects had a disease severity score of 3 (“moderate”) on the 5-point Investigator Global Assessment (IGA) scale, with 8 to 50 inflammatory lesions and no more than two nodules at baseline. The co-primary efficacy endpoints were the percent reduction in inflammatory lesion counts and percentage of subjects with success on IGA, defined as an IGA score of 0 (“clear”) or 1 ( “almost clear”) at Week 10.

The efficacy results are shown in the following table:


Table 3: Inflammatory Lesion Counts and Global Scores in Subjects with Rosacea at Week 10 in a Clinical Trial
 Metronidazole GelVehicle
NResults N (%)NResults N (%)
Inflammatory lesions557 189 
Baseline, mean count 18.3 18.4
Week-10, mean count 8.9 12.8
Reduction 9.4 (50.7) 5.6 (32.6)
Investigator Global Assessment557 189 
Subject clear or almost clear 214 (38.42) 52 (27.51)
Subject with no change 159 (28.5) 77 (40.7)

Subjects treated with Metronidazole Gel experienced a mean reduction of 9.4 inflammatory lesions in the Week-10 LOCF group, compared to a reduction of 5.6 for those treated with vehicle, or a difference in means of 3.8 lesions.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

How Supplied
Metronidazole Gel is clear, colorless to pale yellow in color, and supplied as follows:
55 gram pump – NDC 68308-663-55
60 gram tube – NDC 68308-663-60

Storage and Handling
Store at controlled room temperature: 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (59° and 86°F).

17 PATIENT COUNSELING INFORMATION

PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Administration Instructions
Use as directed. Avoid contact with the eyes [see Warnings and Precautions (5.4)].
Cleanse treated areas before the application of Metronidazole Gel [see Dosage and Administration (2)]
Advise patients to report any adverse reaction to their healthcare providers.

Neurologic Disease
Advise patients to immediately report any abnormal neurologic signs to their healthcare provider [see Warnings and Precautions (5.1)].

Lactation
Advise women not to breastfeed during treatment with Metronidazole Gel [see Use in Specific Populations (8.2)].

Rx Only
US Patent No. 6,881,726 and 7,348,317
Distributed by:
Mayne Pharma
Raleigh, NC 27609 
P58252-0
Product of Canada
All trademarks are the property of their respective owners.

PATIENT INFORMATION

PATIENT MEDICATION INFORMATION SECTION

Metronidazole Gel

Important: Metronidazole Gel is for use on the skin only (topical use). Do not use Metronidazole Gel in your mouth, eyes, or vagina.

What is Metronidazole Gel?
Metronidazole Gel is a prescription medicine used on the skin (topical) to treat pimples and bumps (inflammatory lesions) caused by a condition called rosacea.
It is not known if Metronidazole Gel is safe and effective in children.

Do not use Metronidazole Gel if you are allergic to metronidazole or any of the ingredients in Metronidazole Gel. See the end of this leaflet for a complete list of ingredients in Metronidazole Gel.

Before using Metronidazole Gel, tell your healthcare provider about all your medical conditions, including if you:

  • have tingling or numbness in your hands or feet
  • have or have had a blood disorder or disease
  • are pregnant or plan to become pregnant. It is not known if Metronidazole Gel will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if Metronidazole Gel passes into your breast milk. Do not breastfeed during treatment with Metronidazole Gel. Talk to your healthcare provider about the best way to feed your baby during treatment with Metronidazole Gel.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I use Metronidazole Gel?

  • Use Metronidazole Gel exactly as your healthcare provider tells you to.
  • Cleanse the treated area before applying Metronidazole Gel.
  • Apply and rub in a thin film of Metronidazole Gel 1 time a day to the affected area(s).
  • You can apply cosmetics after applying Metronidazole Gel. 
  • Avoid contact of Metronidazole Gel with your eyes.

What are the possible side effects of Metronidazole Gel?
Metronidazole Gel may cause serious side effects, including:

  • Peripheral neuropathy. Tingling, burning, pain or numbness in the hands or feet (peripheral neuropathy) have happened in people treated with metronidazole used on the skin. Tell your healthcare provider if you experience tingling, burning, pain or numbness in your hands or feet during treatment with Metronidazole Gel.
  • Skin reactions, including allergic reactions. Tell your healthcare provider if you develop any skin reactions, including rash, itching, redness, swelling, or blisters during treatment with Metronidazole Gel. 
  • Eye irritation. Tearing from eye irritation has happened in people treated with metronidazole used on the skin. Tell your healthcare provider if you experience tearing, redness or discomfort of the eyes during treatment with Metronidazole Gel.

The most common side effects of Metronidazole Gel include:

  • sore throat and nasal congestion
  • upper respiratory tract infections
  • headache

Tell your healthcare provider if you get any side effects during treatment with Metronidazole Gel.

These are not all of the possible side effects of Metronidazole Gel.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
You may also report side effects to Mayne Pharma at 1-844-825-8500.

How should I store Metronidazole Gel?

  • Store Metronidazole Gel at room temperature between 68°F to 77°F (20°C to 25°C).

Keep Metronidazole Gel and all medicines out of the reach of children.

General information about the safe and effective use of Metronidazole Gel.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Metronidazole Gel for a condition for which it was not prescribed. Do not give Metronidazole Gel to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Metronidazole Gel that is written for health professionals.

What are the ingredients in Metronidazole Gel?
Active ingredient:
metronidazole
Inactive ingredients: betadex, edetate disodium, hydroxyethyl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparaben and purified water

Distributed by:
Mayne  Pharma
Raleigh, NC 27609
P58252-0
Product of Canada
US Patent No. 6,881,726 and 7,348,317

This Patient Information has been approved by the U.S. Food and Drug Administration.
Revised 10/2024

PACKAGE LABEL - 55g pump

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

55-g-carton-image
55-g-carton-image

NDC 68308-663-55

Metronidazole Gel 1%

Pump

For topical use only


Rx Only

NET WT. 55g
maynepharma


For topical use only.
Not for oral, ophthalmic or intravaginal use.

Store at controlled room temperature, 68° to 77°F (20° - 25°C), excursions permitted between 59° to 86°F (15° - 30°C).
Keep out of reach of children.

Usual dosage: Apply a thin film once a day to the affected areas.  See package insert for complete prescribing instructions.


Each gram contains: 10 mg (1%) metronidazole as active ingredient in a gel base consisting of betadex, edetate disodium, hydroxyethl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparben, and purified water.



Distributed by:
Mayne Pharma
Raleigh, NC 27609
Product of Canada.

P57418-0

PACKAGE LABEL - 60g Tube

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

60g-carton-image
60g-carton-image

NDC 68308-663-60
Metronidazole Gel
1% 
For Topical Use Only

Rx Only
Net Wt. 60 g

maynepharma

Product of Canada
Distributed by:
MaynePharma
Raleigh, NC 27609

P58251-0


FOR TOPICAL USE ONLY. NOT FOR ORAL, OPHTHALMIC OR INTRAVAGINAL USE.
STORE AT CONTROLLED ROOM TEMPERATURE 68º TO 77ºF(20º - 25º C)
EXCURSIONS PERMITTED BETWEEN 59º AND 86ºF (15º - 30ºC)


Usual dosage: Apply a thin film once a day to the affected areas. 
See package insert for complete prescribing instructions.

Each gram contains: Active: 10 mg (1%) metronidazole as active ingredient in a gel base consisting of betadex, edetate disodium, hydroxyethl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparben, and purified water.

See crimp of tube for lot number and expiration date.


DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
577237metroNIDAZOLE 1 % Topical GelPSN2
577237metronidazole 0.01 MG/MG Topical GelSCD2
577237metronidazole 1 % Topical GelSY2

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
METRONIDAZOLE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
8ffb9b1d-3ed7-ba2e-677e-47d4d134fd55Product name520251024
7f6d14e0-4366-41bc-a4a9-b74c79a20e17Product name120250623
e6d321b0-0e5e-7da6-f043-92b6a91f00a1Product name520250515
e1aac33b-94ae-4ee9-905b-299f7263853bProduct name320250124
16642716-d28a-4f90-8dcb-3921cd8c8109Product name420240516
0be8e4ae-4d57-49f3-b3a9-e4728b4e8d15Product name120240313
dea2eded-d1e7-46bb-9a3d-f8dc20de6277Product name120190408
a5070875-62bb-61e1-fd46-8f7054197a40Product name820180215
0add4de9-d152-3375-3390-1123dddc5e3dProduct name120140508
33ca0fcc-1011-92dc-50a9-a383683eed1eProduct name120140508
53f39d9f-cd3f-04e1-c668-d4580719d57dProduct name120140508
a804000f-b74f-0b5d-d17b-aa767c286ddbProduct name120140508
a91ea265-6e02-c08f-93c8-686d54180529Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
68308-663-55Metronidazole1 in 1 CARTONGEL12
68308-663-55Metronidazole55 g in 1 BOTTLE, PUMPGEL552
68308-663-60Metronidazole60 g in 1 TUBEGEL602
68308-663-60Metronidazole1 in 1 CARTONGEL12

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
68308-663METRONIDAZOLE GEL [MAYNE PHARMA INC.]2Current NDC, 4 package rows20250515_3c25a3f9-52fc-448e-a044-f63b9dadcd4a.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
68308-663-55GM - Gram68308-663b1538d0d-bcaf-4ae3-a270-d1987d2b14b812024-01-04
68308-663-60GM - Gram68308-663131d2422-ed02-4647-a7a6-06f5d30b654012025-06-13

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
68308-66368308-663-55, 68308-663-60

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N021789-001METROGELMETRONIDAZOLE1%GEL / TOPICALABRLD, RS2005-06-30

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
N021789-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30c2088c7a36db…
2026-09-14 22:38:342026-08N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-3084e616aacf4f…
2026-08-18 06:07:402026-07N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-3031067a03dcf5…
2025-08-23 18:47 UTC2025-08N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-306a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-3003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-302680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-305bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-3079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-301e350fbaab3a…
2024-05-31 18:47 UTC2024-05N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-308072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-305c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-305d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-304b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-3074a2ff9319b5…
2022-03-09 01:35 UTC2022-03N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-3087673890dc5c…
2021-03-12 10:30 UTC2021-03N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-305aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-308869cabd3fbd…
2020-11-12 02:37 UTC2020-11N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30c0c555d07b60…
2019-12-14 00:12 UTC2019-12N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-303f01610625f2…
2019-09-15 20:21 UTC2019-09N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30b00525d2431f…
2019-07-19 19:46 UTC2019-07N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-306a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-301c564ffb4f44…
2023-12-20 04:57 UTC2023-12N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-309b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-303f0d92c62455…
2023-05-13 08:27 UTC2023-05N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-30053a50430f4f…
2023-01-26 05:58 UTC2023-01N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-303bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N021789-001METROGEL1%GEL / TOPICALABRLD, RS2005-06-303a93d1ddd44b…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-10-15 13:18:302026-09N021789-001AB1c2088c7a36db…
2026-09-14 22:38:342026-08N021789-001AB184e616aacf4f…
2026-08-18 06:07:402026-07N021789-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N021789-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N021789-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08N021789-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N021789-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N021789-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N021789-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N021789-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N021789-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N021789-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N021789-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N021789-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N021789-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N021789-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N021789-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N021789-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N021789-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N021789-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N021789-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03N021789-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N021789-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N021789-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03N021789-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N021789-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11N021789-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12N021789-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09N021789-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07N021789-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N021789-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N021789-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12N021789-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N021789-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N021789-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N021789-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N021789-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05N021789-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01N021789-001AB13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N021789-001AB13a93d1ddd44b…

Observed Orange Book patent history#

Captured, Edition, Application-product table
CapturedEditionApplication-productPatentExpirationUse codeCoverage / statusSubmission dateSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N021789-00168817262022-02-21U-743Drug product5c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N021789-00173483172022-02-21U-743Drug product5c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N021789-00168817262022-02-21U-743Drug product5d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N021789-00173483172022-02-21U-743Drug product5d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N021789-00168817262022-02-21U-743Drug product4b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N021789-00173483172022-02-21U-743Drug product4b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N021789-00168817262022-02-21U-743Drug product74a2ff9319b5…
2019-12-13 00:20 UTC2019-12N021789-00173483172022-02-21U-743Drug product74a2ff9319b5…
2022-03-09 01:35 UTC2022-03N021789-00168817262022-02-21U-743Drug productbb7c543d1eb4…
2022-03-09 01:35 UTC2022-03N021789-00173483172022-02-21U-743Drug productbb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N021789-00168817262022-02-21U-743Drug product782e0a99824c…
2021-12-28 21:50 UTC2021-12N021789-00173483172022-02-21U-743Drug product782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N021789-00168817262022-02-21U-743Drug product87673890dc5c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N021789-00173483172022-02-21U-743Drug product87673890dc5c…
2021-03-12 10:30 UTC2021-03N021789-00168817262022-02-21U-743Drug product5aa47cf7b7d7…
2021-03-12 10:30 UTC2021-03N021789-00173483172022-02-21U-743Drug product5aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N021789-00168817262022-02-21U-743Drug product8869cabd3fbd…
2020-12-22 03:56 UTC2020-12N021789-00173483172022-02-21U-743Drug product8869cabd3fbd…
2020-11-12 02:37 UTC2020-11N021789-00168817262022-02-21U-743Drug productc0c555d07b60…
2020-11-12 02:37 UTC2020-11N021789-00173483172022-02-21U-743Drug productc0c555d07b60…
2019-12-14 00:12 UTC2019-12N021789-00168817262022-02-21U-743Drug product3f01610625f2…
2019-12-14 00:12 UTC2019-12N021789-00173483172022-02-21U-743Drug product3f01610625f2…
2019-09-15 20:21 UTC2019-09N021789-00168817262022-02-21U-743Drug productb00525d2431f…
2019-09-15 20:21 UTC2019-09N021789-00173483172022-02-21U-743Drug productb00525d2431f…
2019-07-19 19:46 UTC2019-07N021789-00168817262022-02-21U-743Drug productea99ee380514…
2019-07-19 19:46 UTC2019-07N021789-00173483172022-02-21U-743Drug productea99ee380514…
2023-01-26 05:58 UTC2023-01N021789-00168817262022-02-21U-743Drug product3bdfa0b2c4d7…
2023-01-26 05:58 UTC2023-01N021789-00173483172022-02-21U-743Drug product3bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N021789-00168817262022-02-21U-743Drug product3a93d1ddd44b…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N021789-00173483172022-02-21U-743Drug product3a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N021789-00168817262022-02-21U-743Drug productf41ea6bd6efb…
2022-10-28 04:53 UTC2022-10N021789-00173483172022-02-21U-743Drug productf41ea6bd6efb…
2022-09-29 23:25 UTC2022-09N021789-00168817262022-02-21U-743Drug producte64feba35796…
2022-09-29 23:25 UTC2022-09N021789-00173483172022-02-21U-743Drug producte64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07N021789-00168817262022-02-21U-743Drug productcb3db0bc1861…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07N021789-00173483172022-02-21U-743Drug productcb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
MetronidazoleMETRONIDAZOLEMayne Pharma Inc.3c25a3f9-52fc-448e-a044-f63b9dadcd4a2024-10-31Warnings, Adverse reactionsExact identifier
ndc (package): 68308-663-55
ndc (package): 68308-663-60
ndc (product): 68308-663
ndc11 (package): 68308066355
ndc11 (package): 68308066360
spl id: a5dc0ad6-1b71-45f9-b00b-cac2f5e2a26b
spl set id: 3c25a3f9-52fc-448e-a044-f63b9dadcd4a

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.